Abstract

The hunt for predictive biomarkers in diseases of the cardio-, cerebro-, and peripheral vascular systems is an ongoing effort and one whose importance cannot be overstated. The identification of subjects most at risk for death or major adverse cardiovascular events may provide a means to stratify diagnostic and therapeutic interventions based on validated predictive algorithms. In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology , de Vos et al1 report that in 252 eligible subjects with documented peripheral arterial disease (PAD) studied at a single center, the measurement of skin autofluorescence (SAF) was independently associated with all-cause mortality and fatal or nonfatal major adverse cardiovascular events after a follow-up period of 5 years. Importantly, the authors excluded subjects with hemodialysis, kidney transplantation, recent myocardial infarction, or recent stroke and report that even after adjustment for cardiovascular risk factors and the use of lipid-lowering drugs, increased SAF remained associated with increased risk for death and major adverse cardiovascular events. A previous report from these authors compared subjects with PAD versus control PAD-free subjects and showed that increased SAF was significantly associated with PAD in a manner independent of traditional cardiovascular risk factors, although such risk factors were associated with further increases in SAF.2 See accompanying article on page 933 The AGE reader was used as a biological marker of advanced glycation endproducts (AGEs) in the skin and is usually tested in the forearm. AGEs are the products of nonenzymatic glycation and oxidation of proteins and lipids. AGEs are increased not only in diabetes mellitus but also in natural aging, oxidative stress, and inflammatory conditions, and in renal failure.3 AGEs form on lysine and arginine residues and are heterogeneous; some AGEs are associated with crosslinking (such as pentosidine), and some AGEs do not fluoresce, such as the carboxy methyl …

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.